Behind the Science: Behind Rethinking Metformin

Metformin has been first-line therapy for type 2 diabetes for decades, but recent advances antiglycemic therapies and new data from the Diabetes Prevention Program Outcomes Study have led to questions around role metformin has carved for itself in armamentarium. At ADA 2022, Endocrinology Network asked experts what they thought of recent data and whether it was time to rethink metformin as a first-line therapy.